Youssef Rddad - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Youssef Rddad's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Youssef Rddad
Verified
Staff Writer, Oncology News Central
Florida
Beats
Sleep Accessories , Food , Mattress Reviews , Sleep
I do not cover celebrities, gossip, business news, religion, science, or technology.
Content
After Enfortumab Vedotin (Padcev) and Pembrolizumab (Keytruda) for Advanced Bladder Cancer, What Next?
By Youssef Rddad Verified| Oncology News Central Verified Enfortumab vedotin (EV) plus pembrolizumab (EV+P) has quickly moved to the forefront of treatment for advanced urothelial carcinoma. This has raised questions about sequencing, resistance, and next lines of treatment. In an interview with Oncology News Central, Parminder Singh, MD, of the Mayo Clinic in Phoenix, outlined approaches to frontline decision-making and shared insights on options after disease progression.
By Youssef Rddad Verified| Oncology News Central Verified Switch maintenance with paclitaxel and ramucirumab extended progression-free survival (PFS) compared with continued first-line chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to final results of a phase 3 study. However, the lack of overall survival (OS) benefit and the trial’s design raise questions about whether the findings will affect practice, an expert said.
After Enfortumab Vedotin (Padcev) and Pembrolizumab (Keytruda) for Advanced Bladder Cancer, What Next?
By Youssef Rddad Verified| Oncology News Central Verified Enfortumab vedotin (EV) plus pembrolizumab (EV+P) has quickly moved to the forefront of treatment for advanced urothelial carcinoma. This has raised questions about sequencing, resistance, and next lines of treatment. In an interview with Oncology News Central, Parminder Singh, MD, of the Mayo Clinic in Phoenix, outlined approaches to frontline decision-making and shared insights on options after disease progression.
Company Info
Oncology News Central
Oncology News Central (ONC) is a digital media outlet focused on providing high-quality information for oncology professionals. Rebranded from OBR Oncology in May 2024, ONC is part of HealthCentral Corp. and aims to improve patient outcomes by delivering comprehensive news and insights tailored to the oncology community. The platform offers a range of services, including breaking clinical news, updates on drug approvals, and detailed coverage of major oncology conferences. It features expert commentary from leading oncologists, educational resources like drug monographs and calculators, and tools related to coding and reimbursement. ONC also provides newsletters and podcasts to keep healthcare providers informed about the latest developments in oncology. Its primary audience includes oncologists and healthcare professionals involved in cancer care, supported by an editorial board of recognized leaders in the field.
'+1 415-332-3327
Founded: 2006